HWHelen White

Helen White

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Helen White has a total of 44 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Development of a Cystic Fibrosis Weight Management Programme: protocol for a co-design study

    by Joanne Barrett, Anne Elizabeth Topping, Nikos Ntoumanis, Alice Margaret Turner, Helen White, Sally Amelia May Fenton

    Background Since the recent introduction of highly effective modulator therapies (HEMT), adults with cystic fibrosis (CF) have experienced significant health improvements. However, HEMTs can also lead to weight gain, and over 30% of adults living with CF, are now overweight or obese. The English National Health Service digital Weight Management Programme (NHS digital WMP) is offered to adults with obesity to support weight loss. This programme may not meet the complex health needs of people living with CF and may not address the established diet and physical activity behaviours that may contribute to weight gain in this population. Methods This paper outlines the steps to co-develop a CF-specific weight management programme (CF WMP), designed to be delivered alongside an NHS digital WMP. The CF-specific programme will be developed in collaboration with people with CF who have overweight or obesity (PwCF ow/ob ) and professional stakeholders, using the three phases of the Person Based Approach (PBA); planning, co-designing and optimising. Planning Mixed-methods research with PwCF ow/ob and CF health care professionals will identify the barriers and facilitators to healthy eating and physical activity experienced by PwCF ow/ob . This will inform the guiding principles to underpin the co-design of the CF WMP and how it will address the dietary and physical activity behavioural needs of PwCF ow/ob to ensure it is engaging, acceptable and motivating. Co-design: a series of participatory workshops with PwCF ow/ob and key stakeholders will use guiding principles to specify design objectives and corresponding intervention features. Optimising: think aloud interviews with PwCF ow/ob will gather feedback on the CF WMP, to iteratively refine the programme. Discussion The resulting CF WMP will extend the usability of an NHS digital WMP to adults with CF, to better ensure it meets their needs, which have changed since the introduction of HEMT.

  • Open Access

    Development of a Cystic Fibrosis Weight Management Programme: protocol for a co-design study

    by Joanne Barrett, Anne Elizabeth Topping, Nikos Ntoumanis, Alice Margaret Turner, Helen White, Sally Amelia May Fenton

    Background Since the recent introduction of highly effective modulator therapies (HEMT), adults with cystic fibrosis (CF) have experienced significant health improvements. However, HEMTs can also lead to weight gain, and over 30% of adults living with CF, are now overweight or obese. The English National Health Service digital Weight Management Programme (NHS digital WMP) is offered to adults with obesity to support weight loss. This programme may not meet the complex health needs of people living with CF and may not address the established diet and physical activity behaviours that may contribute to weight gain in this population. Methods This paper outlines the steps to co-develop a CF-specific weight management programme (CF WMP), designed to be delivered alongside an NHS digital WMP. The CF-specific programme will be developed in collaboration with people with CF who have overweight or obesity (PwCF ow/ob ) and professional stakeholders, using the three phases of the Person Based Approach (PBA); planning, co-designing and optimising. Planning Mixed-methods research with PwCF ow/ob and CF health care professionals will identify the barriers and facilitators to healthy eating and physical activity experienced by PwCF ow/ob . This will inform the guiding principles to underpin the co-design of the CF WMP and how it will address the dietary and physical activity behavioural needs of PwCF ow/ob to ensure it is engaging, acceptable and motivating. Co-design: a series of participatory workshops with PwCF ow/ob and key stakeholders will use guiding principles to specify design objectives and corresponding intervention features. Optimising: think aloud interviews with PwCF ow/ob will gather feedback on the CF WMP, to iteratively refine the programme. Discussion The resulting CF WMP will extend the usability of an NHS digital WMP to adults with CF, to better ensure it meets their needs, which have changed since the introduction of HEMT.

  • Open Access

    Providing Mobile Patient Access to Their Electronic Secondary Care Patient Record in Adults With Cystic Fibrosis: Results of a Prospective, Parallel, Randomized Open-Pilot Quantitative Study

    by Helen K Chadwick, Akhil Sawant, Helen White, Lindsey Gillgrass, Giulia Spoletini, Ian J Clifton, Christine Etherington, Daniel G Peckham

    Background: The Leeds regional adult and pediatric cystic fibrosis (CF) services introduced a modified primary care electronic health care record (EHR) in 2007. This resulted in a dramatic improvement in efficiency while providing the benefits of primary care developments, including full Patient Access to their records. Objective: This study aims to evaluate the feasibility, benefits, usability, and acceptability to patients of providing secure access to linked secondary care in CF. Methods: A prospective, parallel, randomized, open, pilot study with an intervention (EHR access; I) and a control group (no EHR access; C). People with CF were recruited on a consecutive basis, from outpatient clinics or as inpatients on the regional Leeds adult CF unit. At baseline and 6 months, paper-based self-report questionnaires were completed by participants to assess having access to EHR on psychological impact, patient satisfaction, quality of life (QoL), patient and physician relationships, and patterns and rates of adherence to treatment. Perceptions and engagement with Patient Access and computer literacy were also assessed. Once completed, participants were randomized into either the intervention or control group (1:1), with those in the intervention group given instructions about how to gain access and the functions of Patient Access by the research team. Results: A total of 91 people with CF completed the 6-month study (intervention n=45; median age 27.5, IQR 12.0 years; 22 male participants; control group n=46; median age 27.0, IQR 15.0 years; 29 male participants). Median number of logins was 9 (range 1-205). There was no effect of Patient Access on levels of anxiety (Generalized Anxiety Disorder-7; I=3.0, C=5.0), all symptom QoL scales and seven QoL domains (Cystic Fibrosis Questionnaire-Revised; respiratory I=63.89, C=55.56; weight I=100.00, C=66.67; digestion I=88.89, C=88.89; physical I=60.42, C=50.00; vitality I=54.17, C=41.67; emotional I=86.67, C=66.67; role I=75.0, C=75.0; body image I=77.78, C=66.67; eating disturbances I=88.89, C=100.0; treatment burden I=55.56, C=55.56), levels of depression (Patient Health Questionnaire-9; I=3.0, C=7.0), confidence in managing health care (Patient Activation Measure-13; I=66.67, C=60.63), level of trust in health care professionals (patient and provider perceived efficacy in patient-physician interaction; I=49.0, C=47.0), and computer literacy. Patient Access scored 86% for satisfaction, 82% for ease of use, and 80% for usefulness (Perceived Health Web Site Usability Questionnaire). Of those who had EHR access, 41 of 42 (98%) participants agreed that access to EHR should continue. Conclusions: This pilot study suggests that providing access to EHR in adults with CF does not appear to have a negative effect (increase levels of anxiety or decrease QoL), and uptake by patients has been very positive. Prospective studies are needed to investigate the long-term effect on objective health outcomes and how we can improve the functionality of such apps from the patient perspective. Trial Registration: ClinicalTrials.gov NCT06122025; https://clinicaltrials.gov/study/NCT06122025

  • Open Access

    Providing Mobile Patient Access to Their Electronic Secondary Care Patient Record in Adults With Cystic Fibrosis: Results of a Prospective, Parallel, Randomized Open-Pilot Quantitative Study (Preprint)

    by Helen K Chadwick, Akhil Sawant, Helen White, Lindsey Gillgrass, Giulia Spoletini, Ian J Clifton, Christine Etherington, Daniel G Peckham

    BACKGROUND The Leeds regional adult and pediatric cystic fibrosis (CF) services introduced a modified primary care electronic health care record (EHR) in 2007. This resulted in a dramatic improvement in efficiency while providing the benefits of primary care developments, including full Patient Access to their records. OBJECTIVE This study aims to evaluate the feasibility, benefits, usability, and acceptability to patients of providing secure access to linked secondary care in CF. METHODS A prospective, parallel, randomized, open, pilot study with an intervention (EHR access; I) and a control group (no EHR access; C). People with CF were recruited on a consecutive basis, from outpatient clinics or as inpatients on the regional Leeds adult CF unit. At baseline and 6 months, paper-based self-report questionnaires were completed by participants to assess having access to EHR on psychological impact, patient satisfaction, quality of life (QoL), patient and physician relationships, and patterns and rates of adherence to treatment. Perceptions and engagement with Patient Access and computer literacy were also assessed. Once completed, participants were randomized into either the intervention or control group (1:1), with those in the intervention group given instructions about how to gain access and the functions of Patient Access by the research team. RESULTS A total of 91 people with CF completed the 6-month study (intervention n=45; median age 27.5, IQR 12.0 years; 22 male participants; control group n=46; median age 27.0, IQR 15.0 years; 29 male participants). Median number of logins was 9 (range 1-205). There was no effect of Patient Access on levels of anxiety (Generalized Anxiety Disorder-7; I=3.0, C=5.0), all symptom QoL scales and seven QoL domains (Cystic Fibrosis Questionnaire-Revised; respiratory I=63.89, C=55.56; weight I=100.00, C=66.67; digestion I=88.89, C=88.89; physical I=60.42, C=50.00; vitality I=54.17, C=41.67; emotional I=86.67, C=66.67; role I=75.0, C=75.0; body image I=77.78, C=66.67; eating disturbances I=88.89, C=100.0; treatment burden I=55.56, C=55.56), levels of depression (Patient Health Questionnaire-9; I=3.0, C=7.0), confidence in managing health care (Patient Activation Measure-13; I=66.67, C=60.63), level of trust in health care professionals (patient and provider perceived efficacy in patient-physician interaction; I=49.0, C=47.0), and computer literacy. Patient Access scored 86% for satisfaction, 82% for ease of use, and 80% for usefulness (Perceived Health Web Site Usability Questionnaire). Of those who had EHR access, 41 of 42 (98%) participants agreed that access to EHR should continue. CONCLUSIONS This pilot study suggests that providing access to EHR in adults with CF does not appear to have a negative effect (increase levels of anxiety or decrease QoL), and uptake by patients has been very positive. Prospective studies are needed to investigate the long-term effect on objective health outcomes and how we can improve the functionality of such apps from the patient perspective. CLINICALTRIAL ClinicalTrials.gov NCT06122025; https://clinicaltrials.gov/study/NCT06122025

  • Open Access

    Addressing cancer anorexia-cachexia in older patients: Potential therapeutic strategies and molecular pathways

    by Theocharis Ispoglou, Deaglan McCullough, Angela Windle, Sherena Nair, Natalie Cox, Helen White, Dermot Burke, Anastasios Kanatas, Konstantinos Prokopidis


  • Open Access

    The gut microbiota in adults with cystic fibrosis compared to colorectal cancer

    by L.R. Caley, H.M. Wood, D. Bottomley, A. Fuentes Balaguer, L. Wilkinson, J. Dyson, C. Young, H. White, S Benton, M. Brearley, et al.


  • Open Access

    Body mass index and nutritional intake following Elexacaftor/Tezacaftor/Ivacaftor modulator therapy in adults with cystic fibrosis

    by L.R. Caley, H.H. Jarosz-Griffiths, L. Smith, L. Gale, J. Barrett, L. Kinsey, V. Davey, M. Nash, A.M. Jones, J.L. Whitehouse, et al.